Clinical Trials Browser

Phase 3 × brigimadlin × 90 days × Clear all

NCT06058793 2026-01-09

Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma

Phase 3 Completed

Liposarcoma